Lancet: Explore the serum prevalence of anti-SARS-CoV-2 antibodies in the Geneva, Switzerland.

, 20 June 2020 /
Biovalley
BIOON/--- the burden of assessing COVID-19 based on the number of cases in a medical case is not ideal because it relies on detection strategies, changing case definitions, and disease performanceSerum surveys based on population-based measurements of anti-SARS-CoV-2 antibodies provide a way to estimate infection rates and monitor the progressofy of the outbreakIn a new study, researchers from the University Hospital of Geneva, Switzerland, estimated weekly serum prevalence of anti-SARS-CoV-2 antibodies in the Geneva population in Switzerland during the outbreakThe results of the study, recently published in the journal Lancet, are entitled "Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study"images from Lancet, 2020, doi: 10.1016/S0140-6736 (20) 31304-0the study, called SEROCoV-POP, is a population-based study of people who have previously participated in the Bus Sant? study and their family membersThe researchers planned to conduct a series of 12-week serum surveys of participants randomly selected in previous population-representative surveys and their family members ages 5 and olderThey tested each participant's anti-SARS-CoV-2 IgG antibodies using commercially available ELISAThey used the Bayesian logical regression model to estimate serum prevalence, taking into account test performance and adjusting it according to the age and gender of the Geneva populationThey presented the results of the first five weeks of the studyBetween April 6 and May 9, 2020, the researchers recruited 2,766 participants from 1,339 households with a population similar to that of the Canton of GenevaIn the first week, they estimated serum prevalence of 4.8% (95% CI 2.4 to 8.0, n-341)The second week is estimated to increase to 8.5% (5.9 to 11.4, n-469), the third week to 10.9% (7.9 to 14.4, n-577), the fourth week to 6.6% (4.3 to 9.4, n-604), and the fifth week to 10.8% (8.2 to 13.9, n 775)The risk of seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive seropositive semost in people aged 5 to 9 years (relative risk of (RR) 0.32 (95% CI 0.11 to 0.63)) and over 65 years of age (RR 0.50 (0.28 to 0.78))Taking into account the time of serum conversion, they estimated that 11.6 infections were reported in the community for each reported confirmed casethese results show that, despite the high prevalence of COVID-19 in the region (5,000 clinical cases were reported in less than 2.5 months out of a population of 500,000), most of the population in Geneva remained uninfected during the epidemicAssuming the presence of IgG antibodies is related to immunity, these results highlight that the outbreak is far from ending by reducing susceptibility to populationsIn addition, serum prevalence was observed in children aged 5 to 9 years and adults over 65 years of age significantly lower than in people aged 10 to 64These results will inform countries considering relaxing restrictions aimed at curbing transmission(Bio Valley Bioon.com)References:Silvia Stringhini et alSeroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyLancet, 2020, doi:10.1016/S0140-6736 (20) 31304-0.
.